The National Institute for Health and Care Excellence (NICE), the drug approval body for England and Wales, has issued final draft guidance that does not recommend Imnovid (pomalidomide) as a treatment for myeloma patients after third or subsequent relapse. This second negative guidance is based on their opinion that the clinical benefit of Imnovid does not justify its high cost. In particular, they outlined the lack of information on the additional benefit that Imnovid, in combination with dexamethasone, offered over the current standard of care in this setting. A final agreement is expected later in the year but until then, Imnovid will continue to be available in England and Wales via the Cancer Drugs Fund.


Read full article